More news from ASCO meeting

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, including some good news for Germany’s Bayer (BAYN: DE), USA-based Eli Lilly (NYSE: LLY) and the UK’s GlaxoSmithKline (LSE: GSK), adding to cancer drug developments already reported (The Pharma Letter June 4).

Phase III Data on Bayer's regorafenib met primary endpoint in GIST study

Bayer HealthCare announced data from the Phase III GRID (GIST – Regorafenib In Progressive Disease) trial evaluating its investigational drug regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of improvement in progression-free survival (PFS) (HR=0.27, p<0.0001). The median PFS was 4.8 months in the regorafenib arm versus 0.9 months in the placebo arm.